ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02448810
Recruitment Status : Terminated (Based on overall benefit-risk assessment.)
First Posted : May 20, 2015
Results First Posted : March 19, 2018
Last Update Posted : March 19, 2018
Sponsor:
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to compare the efficacy between BAX69 in combination with 5-FU/LV for subjects with KRAS or NRAS mutated tumor (mt) or panitumumab, for subjects with KRAS and NRAS wild type tumor (wt) and standard of care (SoC) per investigator choice as third or fourth treatment line in subjects with progressive measurable metastatic colorectal cancer (mCRC).

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Biological: BAX69 + infusional 5-FU/LV Biological: BAX69 + panitumumab Biological: BAX69 + 5-FU/LV Drug: Standard of Care Biological: Standard of Care Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 115 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Actual Study Start Date : June 15, 2015
Actual Primary Completion Date : February 15, 2017
Actual Study Completion Date : February 15, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)
Subjects stratified according to their mutation status.
Biological: BAX69 + infusional 5-FU/LV

Study Part 1: Safety Run-in

  • Administered weekly as part of a 4 week treatment cycle
  • Intravenous injection
Other Names:
  • Macrophage Migration Inhibitory Factor Antibody (Anti-MIF)
  • Imalumab

Experimental: Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)
Subjects stratified according to their mutation status.
Biological: BAX69 + panitumumab

Study Part 1: Safety Run-in

  • Administered weekly as part of a 4 week treatment cycle
  • Intravenous injection
Other Names:
  • Imalumab
  • Anti-MIF

Experimental: Part 2: Subjects with KRAS or NRAS mutated
Subjects stratified according to their mutation status.
Biological: BAX69 + 5-FU/LV

Study Part 2: Administered weekly as part of a 4 week treatment cycle

•Intravenous injection

Other Names:
  • Imalumab
  • Anti-MIF

Experimental: Part 2: Subjects with KRAS and NRAS wt tumor
Subjects stratified according to their mutation status.
Biological: BAX69 + panitumumab

Study Part 2: Administered weekly as part of a 4 week treatment cycle

•Intravenous injection

Other Names:
  • Imalumab
  • Anti-MIF

Active Comparator: Part 2: Standard of Care- Subjects with KRAS or NRAS mutated
Subjects stratified according to their mutation status.
Drug: Standard of Care
  • Investigator's choice
  • Dose according to drug label

Active Comparator: Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor
Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
Biological: Standard of Care
  • Investigator's choice
  • Dose according to drug label
  • Choice includes panitumumab in KRAS &NRAS wt group only




Primary Outcome Measures :
  1. Part 2: Progression-Free Survival (PFS) [ Time Frame: From start of the study up to safety follow-up visit occurred (30 [-/+7]) days after the last dose of study treatment or until disease progression ]
    PFS was defined as time between treatment initiation and tumor progression (per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1 criteria) or death from any cause, with censoring of participants who were lost to follow-up or withdrew consent.

  2. Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT) [ Time Frame: From start of study treatment up to 28 days ]
    DLT was defined as any drug-related treatment-emergent adverse event (TEAE) (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) that occurs during the first 28 days after treatment start and that meets any of the following criteria: i) Any >= Grade 3 non-hematologic toxicity (excluding: mucositis/stomatitis of Grade 3; diarrhea of <3 days duration; nausea and vomiting <3 days duration; fatigue of <7 days duration; alopecia; single laboratory value out of the normal range that has no clinical significance and that resolves to <= Grade 2 with adequate measures within 7 days) ii) Any Grade 4 hematologic toxicity (excluding: grade 4 neutropenia lasting for <= 5 days; isolated grade 4 lymphocytopenia) iii) Grade 3 febrile neutropenia iv) Grade 3 thrombocytopenia associated with bleeding v) Any life-threatening complication or abnormality not covered in NCI CTCAEv4.03.


Secondary Outcome Measures :
  1. Number of Participants With Occurrence of Binding and/or Neutralizing Anti-imalumab Antibodies [ Time Frame: From start of study drug administration up to end of treatment (EOT) (approximately 21 Months) ]
    Number of participants with occurrence of binding and/or neutralizing anti-imalumab antibodies were reported.

  2. Number of Participants With Incidence of Infusion Reactions After Imalumab Administration [ Time Frame: From start of study drug administration up to EOT (approximately 21 Months) ]
    Infusion reaction was defined as any relevant sign or symptom occurring during or after imalumab infusion and considered by the investigator as an infusion reaction.

  3. Number of Participants With Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From start of study drug administration up to EOT (approximately 21 Months) ]
    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any AE that results in any of the following outcomes: death, a life-threatening event, inpatient hospitalization or prolongation of an existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, other medically important events based upon appropriate medical judgement. TEAEs was defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.

  4. Number of Participants With Response Evaluation According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Day 28 of Cycle 2 followed by every 2 Cycles of 28 day Cycles: Day 56, Day 112, Day 168 and Day 224 ]
    Number of participants with response evaluation according to RECIST v1.1 was evaluated according to complete response (CR): disappearance of all target and non-target lesions and no new lesions; partial response (PR): >= 30 percent (%) decrease in the sum of diameters of target lesions (compared to baseline) and no new lesions; stable disease (SD): neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; progressive disease (PD): >= 20% increase in the sum of diameters of target lesions and an absolute increase in sum of diameters of >=5 millimeter (mm) (compared to the previous minimum sum) or progression of a new lesion.

  5. Overall Survival [ Time Frame: From start of study drug administration up to EOT (approximately 21 Months) ]
    Overall survival was defined as the time from randomization until death due to any cause. Here, number of participants analyzed was based on the number of participants who underwent death.

  6. Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) [ Time Frame: Baseline, 21 Months (EOT) up to follow-up ]
    EORTC QLQ-C30 was a validated instrument used to measure QoL and assess symptoms and side effects of treatment and the impact on everyday life.The QLQ-C30 was composed of: A) 5 multi-item functioning scales(physical, role, social, emotional and cognitive), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a higher level of functioning and a better QoL. B) A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score range from 0 to 100 with a higher score representing a better QoL. C) 9 symptom scales(fatigue, nausea/vomiting,pain,financial impact/difficulties,appetite loss,diarrhea, constipation,sleep disturbance/insomnia and dyspnea), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a greater degree of symptoms and a worse QoL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of a signed informed consent
  2. Male and female subjects 18 years of age and older at the time of screening
  3. Subjects who progressed after receiving at least 2, but no more than 3, prior SoC treatment lines
  4. Anticipated life expectancy >3 months at the time of screening
  5. Weight between 40 kg and 180 kg
  6. Histologically or cytologically confirmed diagnosis of CRC
  7. Metastatic CRC not amenable to surgical resection
  8. Known KRAS and NRAS mutation status (if unknown status for either of these genes, and no archival tissues is available, a fresh tumor biopsy will be made)
  9. At least 1 measurable lesion as defined by RECIST v1.1
  10. ECOG PS of 0-2
  11. Adequate hematological function, defined as:

    1. Platelet count ≥ 100,000/μL
    2. Prothrombin time and activated partial thromboplastin time (aPTT) < 1.5 times the upper limit of normal (ULN)
    3. Absolute neutrophil count (ANC) ≥ 1,000/μL
    4. Hemoglobin ≥ 9 g/dL, without the need for transfusion in the 2 weeks prior to screening
  12. Adequate renal function, defined as serum creatinine ≤ 2.0 times ULN and creatinine clearance > 50 mL/min
  13. Adequate liver function, defined as:

    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)

      ≤ 2.5 times ULN for subjects without liver metastases, or ≤ 5 times ULN in the presence of liver metastases

    2. Bilirubin ≤ 2.0 times ULN, unless subject has known Gilbert's syndrome
  14. Adequate venous access
  15. For female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ 2 forms of adequate birth control measures, including at least 1 barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least 90 days after the last administration of BAX69. Other acceptable contraceptive measures include birth control pills/patches or intrauterine devices
  16. For male subjects, the subject must agree to use adequate contraceptive measures including at least 1 barrier method (eg, condom with spermicidal jelly or foam and [for the female partner] diaphragm with spermicidal jelly or foam, birth control pills/patches, or intrauterine device) and abstain from sperm donation throughout the course of the study and for at least 90 days after the last administration of BAX69
  17. Subject is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

  1. Known central nervous system metastases
  2. Prior malignancy(s) within the past 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, locally advanced prostate cancer, ductal carcinoma in situ of breast, in situ cervical carcinoma and superficial bladder cancer
  3. Prior treatment with panitumumab for subjects with KRAS and NRAS wt tumor
  4. Residual AE from previous treatment > Grade 1
  5. Prior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumor
  6. Myocardial infarction within 6 months prior to C1D1, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the subject is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)
  7. Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg confirmed upon repeated measures
  8. LVEF < 40% as determined by echocardiogram performed at screening or within 90 days prior to C1D1
  9. QT/QTc interval > 450 msec, as determined by screening ECG performed no earlier than 1 week before C1D1
  10. Prior anti-tumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted therapy, retinoid therapy or hormonal therapy) within 4 weeks prior to C1D1.
  11. Major surgery within 4 weeks prior to C1D1
  12. Active joint inflammation or history of inflammatory arthritis or other immune disorder involving joints
  13. Active infection involving IV antibiotics within 2 weeks prior to C1D1
  14. Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
  15. Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease
  16. Subject has received a live vaccine within 4 weeks prior to C1D1
  17. Known hypersensitivity to any component of recombinant protein production by CHO cells
  18. Exposure to an investigational product or investigational device in another clinical study within 4 weeks prior to C1D1, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study
  19. Subject is nursing or intends to begin nursing during the course of the study
  20. Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, ECG), that in medical judgment of the investigator may impede the subject's participation in the study, pose increased risk to the subject, and/or confound the results of the study
  21. Subject is a family member or employee of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02448810


Locations
United States, Florida
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States, 34952
United States, Illinois
Joliet Oncology-Hematology Associates, Ltd.
Joliet, Illinois, United States, 60435
United States, Indiana
Indiana University Health
Goshen, Indiana, United States, 46526
United States, Maryland
Maryland Oncology Hematology, P.A.
Rockville, Maryland, United States, 20850
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New York
Montefiore Einstein Center for Cancer Care
Bronx, New York, United States, 10461
Mount Sinai Beth Israel
New York, New York, United States, 10003
United States, Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
United States, South Carolina
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States, 29412
United States, Tennessee
The Jones Clinic, PC
Germantown, Tennessee, United States, 38138
United States, Texas
Mary Crowley Cancer Research Center
Dallas, Texas, United States, 75230
CTRC at University of Texas Health Science Center
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Baxalta now part of Shire
Investigators
Study Director: Rekha Abichandani, MD, MS Baxalta now part of Shire
  Study Documents (Full-Text)

Documents provided by Shire ( Baxalta now part of Shire ):
Study Protocol  [PDF] May 9, 2016
Statistical Analysis Plan  [PDF] October 10, 2016


Responsible Party: Baxalta now part of Shire
ClinicalTrials.gov Identifier: NCT02448810     History of Changes
Other Study ID Numbers: 391401
2015-000896-28 ( EudraCT Number )
First Posted: May 20, 2015    Key Record Dates
Results First Posted: March 19, 2018
Last Update Posted: March 19, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Fluorouracil
Antibodies, Monoclonal
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs